Biopartnering Seminar - `What New Product Could A Firm Like IMS Health Develop For Clients?'

ParaNovum Team Photo
Tuesday, November 29, 2016 - 6:30pm

Quintiles and IMS Health have recently merged to become the world’s largest Contract Research Organization (CRO), supporting pharmaceutical company’s clinical, medical and commercial operations. Their portfolio of products and services span the entire healthcare value chain from pre-clinical R&D through to commercial execution and real-world patient outcomes. Within the pharmaceutical industry, patient retention during clinical trials is a growing concern as trials continue to grow in complexity and duration. The cause of poor patient retention, or high dropout rates have been linked to a lack of study protocol comprehension, due to outdated consent methods, and a lack of patient engagement throughout the study. To address these concerns, we propose a new product for the QuintilesIMS portfolio called QuInteract, an interactive platform application developed to help clinical trial investigators better engage patients throughout the trial period. QuInteract will enhance the consent process using a multimedia library, medical terminology section, and questionnaire to ensure complete patient comprehension of study protocol, risks, and benefits. Furthermore, QuInteract will include an interactive timeline with push notifications where patients can see upcoming appointments, connect directly to study investigators and report adverse events and symptoms in real time. This technology has the potential to revolutionize patient engagement and improve the success of clinical trials around the world. 

Presenting Team: ParaNovum Group

Team Members: Connor Downs, Bryan Brodie, Alexandra Cordner, Mark Volk, Jessica Masciangelo, Mawleshan Pathmarajah

Date: November 29th at 6:30pm

Location: Instructional Centre, Room 120

All welcome! Light refreshments will be served outside of Room 120 at 6pm.